In contrast to the previous findings that BRAF/TERT promoter double-mutated brain tumor cells (26) were hypersensitive against the ETS inhibitor YK-4-279, we found that YK-4-279 reduced the expression of TERT and conferred the anti-tumor activity independent of TERT promoter mutations in thyroid cancer cells. This evidence concerns the gene BRAF and thyroid gland carcinoma.